Download
art:10.1186/s13075-016-1098-7.pdf 1,25MB
WeightNameValue
1000 Titel
  • Active but not inactive granulomatosis with polyangiitis is associated with decreased and phenotypically and functionally altered CD56dim natural killer cells
1000 Autor/in
  1. Merkt, Wolfgang |
  2. Blank, Norbert |
  3. Hundemer, Michael |
  4. Cerwenka, Adelheid |
  5. Lorenz, Hanns-Martin |
  6. Claus, Maren |
  7. Watzl, Carsten |
1000 Erscheinungsjahr 2016
1000 LeibnizOpen
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2016-09-13
1000 Erschienen in
1000 Quellenangabe
  • 18:204
1000 FRL-Sammlung
1000 Copyrightjahr
  • 2016
1000 Lizenz
1000 Verlagsversion
  • http://doi.org/10.1186/s13075-016-1098-7 |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • BACKGROUND: The role of natural killer (NK) cells in granulomatosis with polyangiitis (GPA) is poorly understood. We recently reported that peripheral blood NK cell percentages correlate with the suppression of GPA activity (cohort I). The purpose of the current study was to further characterize NK cell subsets, phenotype and function in a second GPA cohort (cohort II). METHODS: Peripheral blood lymphocyte subsets were analyzed at a clinical diagnostic laboratory. Clinical data were extracted from medical records and patients were grouped according to their activity state (remission vs. active/non-remission). Separate analysis (cohort II, n = 22) and combined analysis (cohorts I and II, n = 34/57) of NK cell counts/percentages was performed. NK cell subsets and phenotypes were analyzed by multicolor flow cytometry. Cytotoxicity assays were performed using 51 Cr-labeled K562 target cells. RESULTS: In cohort II, NK cell counts were lower than the lower limit of normal in active GPA, despite normal percentages due to lymphopenia. NK cell counts, but not other lymphocyte counts, were significantly higher in remission. Combined analysis of cohorts I and II confirmed decreased NK cell counts in active GPA and increased percentages in long-term remission. Follow-up measurements of six patients revealed increasing NK cell percentages during successful induction therapy. Multicolor analysis from cohort II revealed that in active GPA, the CD56 dim subset was responsible for decreased NK cell counts, expressed more frequently CD69, downregulated the Fc-receptor CD16 and upregulated the adhesion molecule CD54, the chemokine receptor CCR5 and the activating receptor NKG2C. In remission, these markers were unaltered or marginally altered. All other receptors investigated (NKp30, NKp44, NKp46, NKG2D, DNAM1, 2B4, CRACC, 41BB) remained unchanged. Natural cytotoxicity was not detectable in most patients with active GPA, but was restored in remission. CONCLUSIONS: NK cell numbers correlate inversely with GPA activity. Reduced CD56 dim NK cells in active GPA have an activated phenotype, which intriguingly is associated with profound deficiency in cytotoxicity. These data suggest a function for NK cells in the pathogenesis and/or modulation of inflammation in GPA. NK cell numbers, phenotype (CD16, CD69, NKG2C) or overall natural cytotoxicity are promising candidates to serve as clinical biomarkers to determine GPA activity.
1000 Sacherschließung
lokal CD16
lokal Vasculitis
lokal NKG2C
lokal Natural killer cells
lokal CD54
lokal Natural cytotoxicity
lokal CCR5
lokal Fc receptor
lokal Granulomatosis with polyangiitis
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/creator/TWVya3QsIFdvbGZnYW5n|https://frl.publisso.de/adhoc/creator/QmxhbmssIE5vcmJlcnQ=|https://frl.publisso.de/adhoc/creator/SHVuZGVtZXIsIE1pY2hhZWw=|https://frl.publisso.de/adhoc/creator/Q2Vyd2Vua2EsIEFkZWxoZWlk|https://frl.publisso.de/adhoc/creator/TG9yZW56LCBIYW5ucy1NYXJ0aW4=|http://orcid.org/0000-0001-8732-0645|http://orcid.org/0000-0001-5195-0995
1000 Label
1000 Förderer
  1. Roche Pharma AG |
  2. Leibniz Association |
1000 Fördernummer
  1. -
  2. SAW-2013-IfADo-2
1000 Förderprogramm
  1. -
  2. Open Access fund
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer Roche Pharma AG |
    1000 Förderprogramm -
    1000 Fördernummer -
  2. 1000 joinedFunding-child
    1000 Förderer Leibniz Association |
    1000 Förderprogramm Open Access fund
    1000 Fördernummer SAW-2013-IfADo-2
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6403472.rdf
1000 Erstellt am 2017-07-14T10:50:52.938+0200
1000 Erstellt von 122
1000 beschreibt frl:6403472
1000 Bearbeitet von 288
1000 Zuletzt bearbeitet 2021-03-04T07:54:02.648+0100
1000 Objekt bearb. Thu Mar 04 07:54:02 CET 2021
1000 Vgl. frl:6403472
1000 Oai Id
  1. oai:frl.publisso.de:frl:6403472 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source